Financial Tables | Printer Friendly Version

Highlights:

  • Revenue of $1.72 billion represents 8% reported growth year-over-year; and up 13% on a core(1) basis.

  • GAAP net income of $329 million with earnings per share (EPS) of $1.10, up 28% from the third quarter of 2021.

  • Non-GAAP(2) net income of $401 million with EPS of $1.34, up 22% from the third quarter of 2021. 

  • Full-year guidance raised with revenue now expected to be in the range of $6.750 billion to $6.775 billion, representing reported growth of 6.8% to 7.2% and core(1) growth of 9.9% to 10.3%. Full-year non-GAAP(3) EPS is also raised to an estimated range of $5.06 to $5.08 per share. 

  • Fourth-quarter revenue expected to be in the range of $1.750 billion to $1.775 billion with non-GAAP(3) EPS of $1.38 to $1.40. 

Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.72 billion for the third quarter ended July 31, 2022, an increase of 8% compared to the third quarter of 2021 and up 13% on a core(1) basis.

Third-quarter GAAP net income was $329 million, or $1.10 per share. This compares with $264 million, or 86 cents per share, in the third quarter of fiscal year 2021. Non-GAAP(2) net income was $401 million, or $1.34 per share during the quarter, compared with $337 million or $1.10 per share during the third quarter a year ago.

“The Agilent team delivered an excellent quarter,” said Agilent President and CEO Mike McMullen. “The strong results in Q3, coupled with orders continuing to outpace revenues, highlight the ongoing strength and momentum of our diversified business. We are once again raising our full-year revenue and earnings outlook.”

Financial Highlights

In the first quarter of 2022, Agilent implemented certain changes to its segment reporting structure. Prior period segment information has been recast to reflect these changes. These changes have no impact on Agilent’s consolidated financial statements.

Life Sciences and Applied Markets Group

Agilent’s Life Sciences and Applied Markets Group (LSAG) reported third-quarter revenue of $1.019 billion, a year over year increase of 14% (up 18% on a core(1) basis). LSAG’s operating margin for the quarter was 30.5%. 

Agilent CrossLab Group

The Agilent CrossLab Group (ACG) reported third-quarter revenue of $359 million, a year over year increase of 5% (up 10% on a core(1) basis). ACG’s operating margin for the quarter was 24.6%. 

Diagnostics and Genomics Group

The Diagnostics and Genomics Group (DGG) reported third-quarter revenue of $340 million, a year over year decrease of 2% (up 3% on a core(1) basis). DGG’s operating margin for the quarter was 21.5%.

Full Year and Fourth-Quarter Outlook

Agilent has increased its outlook and expects full-year revenue to be in the range of $6.750 billion to $6.775 billion, representing reported growth of 6.8% to 7.2% and core(1) growth of 9.9% to 10.3%. Agilent has also increased full-year non-GAAP(3) EPS to an estimated range of $5.06 to $5.08 per share.

The outlook for fourth-quarter revenue is expected to be in a range of $1.750 billion to $1.775 billion. Fourth-quarter non-GAAP(3) earnings guidance is expected to be in the range of $1.38 to $1.40 per share.

The outlook is based on July 31, 2022, currency exchange rates.

Conference Call

Agilent’s management will present additional details regarding the company’s third-quarter 2022 financial results on a conference call with investors today at 1:30 p.m. PDT. This event will be broadcast live online in listen-only mode. To listen to the webcast, select the “Q3 2022 Agilent Technologies Inc. Earnings Conference Call” link on the Agilent Investor Relations website. The webcast will remain on the company site for 90 days.

Forward-Looking Statements

This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding Agilent’s growth prospects, business, financial results, revenue, and non-GAAP earnings guidance for Q4 and fiscal year 2022 and future amortization of intangibles. These forward-looking statements involve risks and uncertainties that could cause Agilent’s results to differ materially from management’s current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of Agilent’s customers’ businesses; unforeseen changes in the demand for current and new products, technologies, and services; unforeseen changes in the currency markets; customer purchasing decisions and timing; and the risk that Agilent is not able to realize the savings expected from integration and restructuring activities. In addition, other risks that Agilent faces in running its operations include the ability to execute successfully through business cycles; the ability to meet and achieve the benefits of its cost-reduction goals and otherwise successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross-margin pressures; the risk that its cost-cutting initiatives will impair its ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties and global economic conditions on its operations, its markets and its ability to conduct business; the ability to improve asset performance to adapt to changes in demand; the ability of its supply chain to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix; the ability of Agilent to successfully integrate recent acquisitions; the ability of Agilent to successfully comply with certain complex regulations; the adverse impacts of and risks posed by the COVID-19 pandemic; and other risks detailed in Agilent’s filings with the Securities and Exchange Commission, including its quarterly report on Form 10-Q for the fiscal quarter ended April 30, 2022. Forward-looking statements are based on the beliefs and assumptions of Agilent’s management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.

(1) Core revenue growth excludes the impact of currency and acquisitions and divestitures within the past 12 months. Core revenue is a non-GAAP measure. Reconciliations between GAAP revenue and core revenue for Q3 fiscal year 2022 are set forth on page 6 of the attached tables along with additional information regarding the use of this non-GAAP measure. Core revenue growth rate as projected for Q4 fiscal year 2022 and full fiscal year 2022 excludes the impact of currency and acquisitions and divestitures within the past 12 months. Most of the excluded amounts pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy and could differ materially. Therefore, no reconciliation to GAAP amounts has been provided for the projection.

(2) Non-GAAP net income and non-GAAP earnings per share primarily exclude the impacts of non-cash asset impairments, intangibles amortization, transformational initiatives, acquisition and integration costs, change in fair value of contingent consideration, loss on extinguishment of debt, business exit and divestiture costs and net loss (gain) on equity securities. Agilent also excludes any tax benefits or expenses that are not directly related to ongoing operations and which are either isolated or are not expected to occur again with any regularity or predictability. A reconciliation between non-GAAP net income and GAAP net income is set forth on page 4 of the attached tables along with additional information regarding the use of this non-GAAP measure.

(3) Non-GAAP earnings per share as projected for Q4 fiscal year 2022 and full fiscal year 2022 exclude primarily the impacts of non-cash intangibles amortization, transformational initiatives, and acquisition and integration costs. Agilent also excludes any tax benefits or expenses that are not directly related to ongoing operations and which are either isolated or are not expected to occur again with any regularity or predictability. Most of these excluded amounts pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy and could differ materially. Therefore, no reconciliation to GAAP amounts has been provided. Future amortization of intangibles is expected to be approximately $41 million per quarter.